1-cyclopentylidene-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine | 444286-24-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-cyclopentylidene-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine
• 英文别名: N-(cyclopentylideneamino)-4-(3-nitrophenyl)-1,3-thiazol-2-amine
• CAS: 444286-24-2
• 化学式: C₁₄H₁₄N₄O₂S
• 分子量: 302.357
• InChiKey: CQPTUWPFQMZPJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  环戊酮 在 溶剂黄146 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 0.28h， 生成 1-cyclopentylidene-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine
  参考文献：
  名称：

  评价作为组蛋白乙酰转移酶抑制剂的（噻唑-2-基））酮和类似物的大型文库：酶和细胞研究

  摘要：

  最近，我们描述了一些（噻唑-2-基）azo作为抗原生动物，抗真菌和抗MAO试剂以及Gcn5 HAT抑制剂。在这些最后的化合物中，CPTH2和CPTH6在细胞中显示出HAT抑制作用和广泛的抗癌特性。为了鉴定比两个原型更有效的HAT抑制剂，我们合成了几种新的（噻唑-2-基）azo酮，包括一些相关的噻唑烷和嘧啶4（3 H）-酮，并测试了我们现有的整个文库针对人p300和PCAF HAT酶的实验室。某些化合物（1x，1c '，1d '，1i '和2m）在抑制p300 HAT酶方面比CPTH2和CPTH6更有效。在人白血病U937和结肠癌HCT116细胞（100μM，30小时）中进行测试时，1x，1i '和2m产生的凋亡（U937细胞）或类似细胞（HCT116细胞）高于CPTH6，并且在诱导细胞分化方面比CPTH6更有效（U937细胞）。

  DOI：

  10.1016/j.ejmech.2014.04.042

文献信息

• Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents
  作者：Simone Carradori、Francesco Ortuso、Anél Petzer、Donatella Bagetta、Celeste De Monte、Daniela Secci、Daniela De Vita、Paolo Guglielmi、Gokhan Zengin、Abdurrahman Aktumsek、Stefano Alcaro、Jacobus P. Petzer

  DOI：10.1016/j.ejmech.2017.10.050

  日期：2018.1

  acetylcholinesterase (AChE) inhibitors, as well as antioxidant agents, for the treatment of neurodegenerative disorders such as Parkinson's disease. Rational molecular design, target recognition and predicted pharmacokinetic properties have been evaluated by means of molecular modelling. Based on these properties, compounds were synthesized and evaluated in vitro as MAO-B and AChE inhibitors, and compared to

  新型的4-（3-硝基苯基）噻唑-2-基hydr衍生物被提议作为双靶标定向单胺氧化酶B（MAO-B）和乙酰胆碱酯酶（AChE）抑制剂，以及抗氧化剂，用于治疗神经退行性疾病，例如作为帕金森氏病。合理的分子设计，目标识别和预测的药代动力学特性已经通过分子建模进行了评估。基于这些特性，合成了化合物并作为MAO-B和AChE抑制剂进行了体外评估，并与相应的同工酶单胺氧化酶A（MAO-A）和丁酰胆碱酯酶（BuChE）的活性进行了比较。还已经在体外研究了抗氧化特性，这些特性在治疗神经退行性疾病中可能有用。在评估的化合物中，三种抑制剂可以被认为是有希望的体外MAO-B和AChE双重抑制剂。对于化合物19， MAO-B抑制作用也显示出竞争性和可逆性。
• [EN] NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER<br/>[FR] MODULATEURS NAT10 POUR LE TRAITEMENT OU LA PRÉVENTION DES LAMINOPATHIES, DU VIEILLISSEMENT ET DU CANCER
  申请人：CAMBRIDGE ENTPR LTD

  公开号：WO2015150824A1

  公开（公告）日：2015-10-08

  The invention relates to compounds in the treatment or prevention of disorders associated with Lamin A and/or Lamin C depletion or LMNA mutations, such as laminopathy, premature ageing disorders, normal ageing and cancer(such as a cancer characterised by low levels of LMNA expression).

  本发明涉及用于治疗或预防与Lamin A和/或Lamin C耗竭或LMNA突变相关的紊乱的化合物，例如层粘蛋白病，早衰紊乱，正常衰老和癌症（如低水平LMNA表达的癌症）。
• Synthesis and in vitro activity of 2-thiazolylhydrazone derivatives compared with the activity of clotrimazole against clinical isolates of Candida spp.
  作者：Franco Chimenti、Bruna Bizzarri、Elias Maccioni、Daniela Secci、Adriana Bolasco、Rossella Fioravanti、Paola Chimenti、Arianna Granese、Simone Carradori、Daniela Rivanera、Daniela Lilli、Alessandra Zicari、Simona Distinto

  DOI：10.1016/j.bmcl.2007.05.078

  日期：2007.8

  In this paper, we report on the synthesis of a novel series of 2-thiazolylhydrazone derivatives and the influence of the substituents on the thiazole ring on antifungal activity. All synthesized compounds were screened for their in vitro activities against 22 clinical isolates of Candida spp., representing six different species, compared to clotrimazole as a reference compound. Some of the tested compounds were found to possess significant antifungal activity when compared to clotrimazole, in particular compound 14 which exhibited higher potency against most of the Candida spp. considered. The compounds that were most active as anti-Candida agents were also Submitted to cytotoxic screening by the Trypan Blue dye exclusion assay and in general they were shown to induce low cytotoxic effects. (c) 2007 Elsevier Ltd. All rights reserved.
• NAT10 MODULATORS FOR TREATING OR PREVENTING LAMINOPATHIES, AGING AND CANCER
  申请人：Cambridge Enterprise Limited

  公开号：EP3137077A1

  公开（公告）日：2017-03-08
• US9809562B2
  申请人：——

  公开号：US9809562B2

  公开（公告）日：2017-11-07